Twist Bioscience (TWST) and Ginkgo Bioworks (DNA) have renegotiated a previous contract signed in 2022 to provide Twist with key licenses to long DNA technology and assets, the companies said Thursday.
Under the revised $15 million agreement, which runs for three years, Ginkgo will continue to be a valued customer of Twist and will prepay annually for orders of Twist's DNA products. It will also receive preferential pricing for DNA products with no required minimum purchase volume.
Twist will receive licenses and assignments for certain long DNA and other technology as well as related reagents to complement its existing DNA synthesis portfolio of products, and Ginkgo will retain the rights to practice the intellectual property transferred to Twist, the announcement states.
Price: 32.16, Change: -0.63, Percent Change: -1.91
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.